S. Karger AG

SHERPA: Unknown

People

  1. Bodei
    Bodei
  2. Drilon
    Drilon
  3. Motzer
    Motzer
  4. Abou-Alfa
    Abou-Alfa
  5. Chaganti
    Chaganti
  6. Lin
    Lin
  7. Tang
    Tang
  8. Clarkson
    Clarkson
  9. Janjigian
    Janjigian
  10. Marghoob
    Marghoob

Groups

  1. Department of Medicine (279)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)
  7. Sloan Kettering Institute Postdocs (55)
  8. Surgery (54)
  9. Sloan Kettering Institute Faculty (47)
  10. Thoracic Oncology (45)
Search Within
Formats
  1. Meeting Abstract (332)
  2. Journal Article (254)
  3. Book Section (20)
  4. Review (15)
  5. Conference Paper (10)
  6. Book Whole (1)
  7. Editorial (1)
Groups
  1. Department of Medicine (279)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)

More Groups

People
  1. Lisa Bodei (32)
  2. Alexander Drilon (23)
  3. Robert Motzer (23)
  4. Ghassan Abou-Alfa (18)
  5. Steven Hajdu (18)
  6. Oscar Lin (16)

More People

Years
  1. 2025 (3)
  2. 2024 (21)
  3. 2023 (37)
  4. 2022 (42)
  5. 2021 (31)
  6. 2020 (51)

More Years

Publications
  1. Oncology Research and Treatment (226)
  2. Cytogenetics and Cell Genetics (61)
  3. Acta Cytologica (58)
  4. Neuroendocrinology (51)
  5. Acta Haematologica (32)
  6. Onkologie (19)

More Publications

Results (633)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Quality-adjusted life years accrued with cabozantinib in patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial
    Meeting Abstract

    Trojan, J.; Abou-Alfa, G. K.; Mollon, P.; Meyer, T.; Cheng, A. L.; El-Khoueiry, A. B.; Kelley, R. K.; Baron, A. D.; Benzaghou, F.; Valcheva, V.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Safety and efficacy of 12 mg/d lenvatinib (LEN) in patients with unresectable hepatocellular carcinoma (uHCC) and bodyweight (bw) >80 kg in REFLECT
    Meeting Abstract

    Vogel, A.; Kudo, M.; Cheng, A. L.; Sung, M. W.; Finn, R. S.; Lin, A. Y.; Abou-Alfa, G. K.; Alsina, A.; Breder, V.; Tebbutt, N.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Ibrutinib treatment in Waldenström's macroglobulinemia (WM): Follow-up results of the phase 3 iNNOVATE™ study
    Meeting Abstract

    Buske, C.; Tedeschi, A.; Trotman, J.; Garcia-Sanz, R.; Macdonald, D.; Leblond, V.; Mahe, B.; Herbaux, C.; Tam, C. S.; Palomba, M. L.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Integrated population pharmacokinetic (PopPK) modeling of cabozantinib (C) in patients (pts) with various cancer types including advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Geißler, M.; Nguyen, L. T.; Chapel, S.; Meyer, T.; Cheng, A. L.; El-Khoueiry, A. B.; Kelley, R. K.; Abou-Alfa, G. K.; Lacy, S.
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Long-term outcomes in elderly patients (pts) from IMvigor210: Atezolizumab (atezo) in metastatic urothelial cancer (mUC)
    Meeting Abstract

    von Amsberg, G.; Balar, A. V.; Dreicer, R.; Loriot, Y.; Perez-Gracia, J. L.; Hoffman-Censits, J. H.; Petrylak, D. P.; van der Heijden, M. S.; Shen, X.; Ding, B.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • CheckMate 214 patients who discontinued first-line nivolumab + ipilimumab or sunitinib due to treatment-related adverse events
    Meeting Abstract

    Grünwald, V.; Tannir, N. M.; Motzer, R. J.; Plimack, E. R.; McDermott, D. F.; Barthélémy, P.; Porta, C.; George, S.; Powles, T.; Donskov, F.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Grüllich, C.; Rini, B. I.; Huseni, M.; Atkins, M.; McDermott, D.; Powles, T.; Escudier, B.; Banchereau, R.; Liu, L. F.; Leng, N.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Long-term survival outcomes with nivolumab (NIVO) in patients with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response
    Meeting Abstract

    Wohlleber, M.; Brahmer, J.; Borghaei, H.; Ramalingam, S. S.; Horn, L.; Carpeño, J. D.; Pluzanski, A.; Burgio, M. A.; Garassino, M.; Chow, L. Q. M.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • The ECHELON-2 trial: Results of a randomised, double-blind, active-controlled phase 3 study of brentuximab vedotin and CHP (A plus CHP) vs CHOP in the frontline treatment of patients (pts) with CD30(+) peripheral T-cell lymphomas (PTCLs)
    Meeting Abstract

    Trümper, L.; O'Connor, O. A.; Pro, B.; Illidge, T. M.; Advani, R. H.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; Rossi, G.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach
    Meeting Abstract

    Blattmann, C.; Albert, C. M.; Kummar, S.; van Tilburg, C. M.; Dubois, S. G.; Geoerger, B.; Mascarenhas, L.; Federman, N.; Schilder, R. J.; Doz, F.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save